Interaction Checker

Interacciones de Sunitinib

Sunitinib (Sutent) tiene 271 interacciones documentadas en las etiquetas de la FDA y las hojas informativas que indexamos. Graves: 3; moderadas: 267; leves: 1; casos en los que una etiqueta indica que no hay ninguna interacción significativa: 0. Cada entrada de abajo cita la frase que la respalda. Esta página del medicamento es un punto de partida, no un veredicto sobre su situación.

Interacciones según la etiqueta

Interacciones graves (3)

  • BevacizumabGrave

    Thrombotic Microangiopathy (TMA) Thrombotic Microangiopathy (TMA), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, sometimes leading to renal failure or a fatal outcome, occurred in clinical trials and in postmarketing experience of SUTENT as monotherapy and administered in combination with bevacizumab. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Itraconazolantifúngico azólicoGrave

    Axitinib Bosutinib Cabazitaxel Cabozantinib Ceritinib Cobimetinib Crizotinib Dabrafenib Dasatinib Docetaxel Ibrutinib Lapatinib Nilotinib Olaparib Pazopanib Sunitinib Trabectedin Trastuzumab-­emtansine Vinca alkaloids Not recommended during and 2 weeks after TOLSURA treatment. (etiqueta de Itraconazol, Interacciones medicamentosas)

  • Voriconazolantifúngico azólicoGrave

    Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro , but Drug Plasma Exposure Likely to be Increased Avoid concomitant use of voriconazole. (etiqueta de Voriconazol, Interacciones medicamentosas)

Interacciones moderadas (267)

  • AcarbosaantidiabéticoModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AcebutololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ácido etacrínicodiurético de asaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ácido zoledrónicobisfosfonatoModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AdenosinaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AlendronatobisfosfonatoModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AlfuzosinaalfabloqueanteModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • AliskirenoantihipertensivoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Alogliptinainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Alogliptina y metforminainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amiloridadiurético ahorrador de potasioModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AmiodaronaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amitriptilinaantidepresivo tricíclicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Amlodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amlodipino y atorvastatinabloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amlodipino y benazeprilbloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amlodipino y olmesartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Amlodipino y valsartánbloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Anagrelidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Aprepitantinhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Armodafiniloestimulante del SNCModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • AsenapinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • AtazanavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • AtenololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Atenolol y clortalidonabetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Azilsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Azitromicinaantibiótico macrólidoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Benazeprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Benazepril e hidroclorotiazidainhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • BetaxololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Bexagliflozinainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • BisoprololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Bisoprolol e hidroclorotiazidabetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Bosentáninductor de CYP3A4Moderada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Canagliflozinainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Candesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Candesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Captoprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • CarbamazepinaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • CarvedilolbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • CenobamatoanticonvulsivoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • CiclosporinainmunosupresorModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Cimetidinaantagonista H2Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • CiprofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • CitalopramISRSModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Claritromicinaantibiótico macrólidoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • ClobazambenzodiazepinaModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Clonidinaagonista alfa-adrenérgicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • CloroquinaantipalúdicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Clorotiazidadiurético tiazídicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • ClorpromazinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Clortalidonadiurético tiazídicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • ClozapinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Dapagliflozinainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Dapagliflozina y metforminainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • DarunavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Darunavir y cobicistatantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Deferasiroxsuplemento de hierroModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Deutetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • DexametasonacorticosteroideModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Dextrometorfano y quinidinafármaco serotoninérgicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Digoxinaglucósido digitálicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Diltiazembloqueador de los canales de calcioModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Dinitrato de isosorbida e hidralazinanitratoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • DisopiramidaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • DofetilidaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • DoxazosinaalfabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • DronedaronaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Droperidolantagonista de la dopaminaModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Dulaglutidaagonista del receptor de GLP-1Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • EfavirenzantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Efavirenz, lamivudina y tenofovirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Elvitegravir, cobicistat, emtricitabina y tenofovirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Empagliflozinainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Empagliflozina y metforminainhibidor de SGLT2Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Enalaprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Enalapril e hidroclorotiazidainhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Enalaprilatoinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Eplerenonaantagonista de la aldosteronaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Eritromicinaantibiótico macrólidoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • EscitalopramISRSModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • EslicarbazepinaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • EsmololbetabloqueanteModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Espironolactonaantagonista de la aldosteronaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Espironolactona e hidroclorotiazidaantagonista de la aldosteronaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • EtravirinaantirretroviralModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • EverolimusinmunosupresorModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Exenatidaagonista del receptor de GLP-1Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Felodipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • FenitoínaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • FenobarbitalbarbitúricoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • FenoxibenzaminaalfabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Fentermina y topiramatoestimulante del SNCModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • FingolimodinmunosupresorModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • FlecainidaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Fluconazolantifúngico azólicoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • FluoxetinaISRSModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • FosamprenavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Fosaprepitantinhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • FosfenitoínaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Fosinoprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Fosinopril e hidroclorotiazidainhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Furosemidadiurético de asaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • GlibenclamidasulfonilureaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Glibenclamida y metforminasulfonilureaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • GlimepiridasulfonilureaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • GlipizidasulfonilureaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Glipizida y metforminasulfonilureaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Granisetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • GriseofulvinaantifúngicoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Guanfacinaagonista alfa-adrenérgicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • HaloperidolantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • HidralazinavasodilatadorModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Hidroclorotiazidadiurético tiazídicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Hidroxicloroquinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • HidroxizinaantihistamínicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • IbandronatobisfosfonatoModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • IbutilidaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • IloperidonaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Imatinibinhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Indapamidadiurético tiazídicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina aspartainsulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina degludecinsulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina detemirinsulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina glarginainsulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina lisproinsulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Insulina regular (humana)insulinaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Irbesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Irbesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • IsoniazidaantibióticoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Isradipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ivacaftorinhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ketoconazolantifúngico azólicoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • LabetalolbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • LenacapavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • LevofloxacinofluoroquinolonaModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Levotiroxinahormona tiroideaModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Levotiroxina y liotironinahormona tiroideaModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lidocaínaanestésico localModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lidocaína y prilocaínaanestésico localModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Linagliptinainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Linagliptina y metforminainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Liotironinahormona tiroideaModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Liraglutidaagonista del receptor de GLP-1Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lisinoprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lisinopril e hidroclorotiazidainhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lofexidinaagonista alfa-adrenérgicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Loperamidafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Lopinavir y ritonavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Lorlatinibinductor de CYP3A4Moderada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Losartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Losartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MecamilaminaantihipertensivoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MetadonaopioideModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • MetforminabiguanidaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MetildopaantihipertensivoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Metimazolfármaco antitiroideoModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Metolazonadiurético tiazídicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MetoprololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Metoprolol e hidroclorotiazidabetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MexiletinaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Mifepristonainhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MiglitolantidiabéticoModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MinoxidilvasodilatadorModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Mirabegrónagonista beta-adrenérgicoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Mitapivatinductor de CYP3A4Moderada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Mitotanoinductor de CYP3A4Moderada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Modafiniloestimulante del SNCModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Moexiprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • MoxifloxacinofluoroquinolonaModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • NadololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Nafcilinaantibiótico del grupo de las penicilinasModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • NateglinidameglitinidaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • NebivololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • NefazodonaantidepresivoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • NevirapinaantirretroviralModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Nicardipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Nifedipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Nilotinibfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Nirmatrelvir y ritonavirantiviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Nisoldipinobloqueador de los canales de calcio dihidropiridínicoModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • NitroprusiatovasodilatadorModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • OfloxacinofluoroquinolonaModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Olanzapina y fluoxetinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Olmesartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Olmesartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Olmesartán, amlodipino e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ondansetrónfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • OxcarbazepinaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Palbociclibinhibidor de CYP3A4Moderada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PaliperidonaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • PamidronatobisfosfonatoModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Pentamidinafármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • PerampanelanticonvulsivoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Perindoprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PimavanserinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • PimozidaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • PindololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PioglitazonatiazolidinedionaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Pioglitazona y glimepiridatiazolidinedionaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Pioglitazona y metforminatiazolidinedionaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Pitolisantfármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Posaconazolantifúngico azólicoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PrazosinaalfabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PrimidonaanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • ProcainamidaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PrometazinaantihistamínicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Prometazina y codeínaopioideModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Prometazina y dextrometorfanoantihistamínicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • PropafenonaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Propiltiouracilofármaco antitiroideoModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • PropranololbetabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • QuetiapinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Quinaprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Quinapril e hidroclorotiazidainhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • QuinidinaantiarrítmicoModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • QuininaantipalúdicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Ramiprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Ranolazinafármaco que prolonga el intervalo QTModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • RepaglinidameglitinidaModerada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • RifabutinaantibióticoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • RifampicinaantibióticoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • RifapentinaantibióticoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • RisedronatobisfosfonatoModerada

    Concomitant exposure to other risk factors, such as bisphosphonates or dental disease/invasive dental procedures, may increase the risk of ONJ. (etiqueta de Sunitinib, Advertencias y precauciones)

  • RisperidonaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • RitonavirantirretroviralModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Sacubitrilo y valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Saxagliptinainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Saxagliptina y metforminainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Semaglutidaagonista del receptor de GLP-1Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Sitagliptinainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Sitagliptina y metforminainhibidor de la DPP-4Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • SolifenacinaanticolinérgicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • SotalolbetabloqueanteModerada

    Monitor patients who are at higher risk of developing QT interval prolongation, including patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Suvorexantsedante-hipnóticoModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Suzetriginainductor de CYP3A4Moderada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • TacrolimusinmunosupresorModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Tamoxifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Telmisartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Telmisartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Telmisartán y amlodipinoantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TemsirolimusModerada

    Concomitant use of TORISEL with sunitinib The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. (etiqueta de Temsirolimus, Advertencias y precauciones)

  • TerazosinaalfabloqueanteModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Teriparatidahormona tiroideaModerada

    • Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Tetrabenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Ticagrelorantiagregante plaquetarioModerada

    Monitor QT interval more frequently when SUTENT is concomitantly administered with strong CYP3A4 inhibitors or drugs known to prolong QT interval. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TioridazinaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Tirzepatidaagonista del receptor de GLP-1Moderada

    • Hypoglycemia : Check blood glucose levels regularly and assess if antidiabetic drug dose modifications are required. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Tizanidinarelajante muscularModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TolterodinaanticolinérgicoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • TopiramatoanticonvulsivoModerada

    • CYP3A4 Inducers : Consider dose increase of SUTENT when administered with strong CYP3A4 inducers. (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Torasemidadiurético de asaModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Toremifenomodulador selectivo de los receptores de estrógenosModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • TramadolopioideModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Tramadol y paracetamolopioideModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Trandolaprilinhibidor de la ECAModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • TrazodonaantidepresivoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Triamterenodiurético ahorrador de potasioModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Triamtereno e hidroclorotiazidadiurético ahorrador de potasioModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Trióxido de arsénicofármaco que prolonga el intervalo QTModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Valbenazinainhibidor de VMAT2Moderada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Valsartánantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Valsartán e hidroclorotiazidaantagonista de los receptores de la angiotensina II (ARA-II)Moderada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • Vardenafiloinhibidor de la PDE5Moderada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • VenlafaxinaIRSNModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

  • Verapamilobloqueador de los canales de calcioModerada

    Initiate and/or adjust antihypertensive therapy as appropriate. (etiqueta de Sunitinib, Advertencias y precauciones)

  • ZiprasidonaantipsicóticoModerada

    Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etiqueta de Sunitinib, Interacciones medicamentosas)

Menciones leves (1)

  • AxitinibLeve

    MACE occurred in 7% of patients with advanced RCC treated with INLYTA in combination with avelumab compared to 3.4% treated with sunitinib in a randomized trial, JAVELIN Renal 101. (etiqueta de Axitinib, Advertencias y precauciones)

Compruebe Sunitinib frente a todo lo que toma. Añada su lista completa; todos los pares se comprueban a la vez.

Abrir en el verificador

No es un consejo médico. La gravedad refleja la redacción de la etiqueta, no sus circunstancias. Una señal «grave» puede ser algo habitual bajo supervisión y una «leve» puede ser importante a dosis altas. Consulte a un farmacéutico.